Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Prostaglandin E-2-loaded microspheres as strategy to inhibit phagocytosis and modulate inflammatory mediators release

Full text
Author(s):
Nicolete, Roberto [1] ; Lima, Karla de Melo [2] ; Junior, Jose M. R. [2] ; Jose, Peter J. [3] ; Sanz, Maria-Jesus [3, 4] ; Faccioli, Lucia Helena [1]
Total Authors: 6
Affiliation:
[1] Univ Sao Paulo, Dept Anal Clin, BR-14040903 Ribeirao Preto - Brazil
[2] Nanocore Biotecnol Ltda, Campinas, SP - Brazil
[3] Univ Valencia, Dept Pharmacol, Valencia - Spain
[4] Spanish Minist Health, Carlos Hlth Inst 3, Madrid - Spain
Total Affiliations: 4
Document type: Journal article
Source: EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS; v. 70, n. 3, p. 784-790, NOV 2008.
Web of Science Citations: 7
Abstract

PGE(2), an arachidonic acid metabolite produced by various type of cells regulates a broad range of physiological activities in the endocrine, cardiovascular, gastrointestinal, and immune systems, and is involved in maintaining the local homeostasis. In the immune system, PGE(2) is mainly produced by APCs and it can suppress the Th1-mediated immune responses. The aim of this study was to develop PGE(2)-loaded biodegradable MS that prolong and sustain the in vivo release of this mediator. An o/w emulsion solvent extraction-evaporation method was chosen to prepare the MS. We determined their diameters, evaluated the in vitro release of PGE(2), using enzyme immunoassay and MS uptake by peritoneal macrophages. To assess the preservation of biological activities of this mediator, we determined the effect of PGE(2) released from MS on LPS-induced TNF-alpha release by murine peritoneal macrophages. We also analyzed the effect of encapsulated PGE(2) on inflammatory mediators release from HUVECs. Finally, we studied the effect of PGE(2) released from biodegradable MS in sepsis animal model. The use of this formulation can provide an alternative strategy for treating infections, by modulating or inhibiting inflammatory responses, especially when they constitute an exacerbated profile. (C) 2008 Elsevier B.V. All rights reserved. (AU)

FAPESP's process: 02/12856-2 - Modulation of innate and acquired immune responses by leukotrienes and prostaglandins
Grantee:Lúcia Helena Faccioli
Support Opportunities: Research Projects - Thematic Grants